Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Market Closed - Xetra Other stock markets 11:35:56 2025-01-24 am EST			5-day change	1st Jan Change
20.90 ^EUR	-0.85%		-1.18%	+8.19%

Jan. 23	Bayer Teams Up with Pula Foundation to Insure Smallholder Farmers in Africa, Asia	MT
Jan. 23	Bayer: climate insurance project for farmers	CF

Bayer: new Nubeqa application filed in the USA

November 21, 2024 at 08:15 am EST

Bayer announced on Friday that it had filed a supplemental new drug application (sNDA) with the U.S. Food and Drug Administration (FDA) for Nubeqa in the treatment of hormone-sensitive metastatic prostate cancer (mHSPC).

The German pharmaceutical group says it is basing its application on the favorable results of a Phase III study recently presented at the European Society for Medical Oncology (ESMO) congress.

Nubeqa, developed in collaboration with the Finnish laboratory Orion, is currently approved in the USA for the treatment of mHSPC in combination with docetaxel, a type of chemotherapy.

The product is also approved for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC).

Copyright (c) 2024 CercleFinance.com. All rights reserved.

Go to the original article.
Legal disclaimer

Latest news about Bayer AG

Bayer Teams Up with Pula Foundation to Insure Smallholder Farmers in Africa, Asia	Jan. 23	MT
Bayer: climate insurance project for farmers	Jan. 23	CF
Bayer: exclusive distribution agreement with Ecospray	Jan. 23	CF
Bayer Signs Exclusive Distribution Deal for Ecospray's Nematicide	Jan. 23	MT
BAYER AG : JP Morgan reiterates its Neutral rating	Jan. 21	ZD
BAYER : Xarelto’s decline accelerated	Jan. 20
Formycon receives EU approval for biosimilar to Bayer eye drug	Jan. 20	DP
Formycon stock rises after EU approval of ophthalmic drug	Jan. 20	DP
Formycon's Eylea Biosimilar Gets EU Approval	Jan. 20	MT
German Stocks Surge as Inflation Data Boost Rate Cut Hopes	Jan. 15	MT
Global markets live: Boeing, Pfizer, Nvidia, Goldman Sachs, Shell...	Jan. 15
Bayer Hit with $100 Million Verdict by US Jury Over US School Contamination	Jan. 15	MT
Bayer suffers next PCB defeat in the US – waiting for the highest court in the land	Jan. 15	DP
After Asundexian setback: Bayer optimistic about new blockbusters	Jan. 15	RE
Another setback: Bayer ordered to pay damages in PCB trial	Jan. 15	RE
Bayer Hit with $100 Million Verdict by US Jury Over US School Contamination	Jan. 15	MT
Bayer Aktiengesellschaft Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 10:30 AM	Jan. 14
Bayer pharma chief sees no big acquisitions in near future	Jan. 14	RE
Bayer: first participants in AskBio trial	Jan. 14	CF
Bayer continues to focus on revitalizing its pharmaceuticals business in the medium term – no major deals	Jan. 14	DP
Bayer will focus on debt reduction rather than acquisitions in the coming years	Jan. 14	RE
German Stocks Retreat Amid US Rate Jitters	Jan. 13	MT
Bayer to Commence Late-stage Study for Parkinson's Disease Therapy	Jan. 13	MT
Bayer: towards a Phase III study in Parkinson's disease	Jan. 13	CF
Bayer is starting a crucial cell therapy study for Parkinson's disease	Jan. 13	RE

Chart Bayer AG

Duration

Period

BAYN: Dynamic Chart

Company Profile

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.5%). Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).

Employees

94,245

Sector

Pharmaceuticals

Calendar

2025-03-05 - Q4 2024 Earnings Release

More about the company